Rades Dirk, Nguyen Trang, Janssen Stefan, Schild Steven E
Department of Radiation Oncology, University of Luebeck, 23570 Luebeck, Germany.
Medical Practice for Radiotherapy and Radiation Oncology, 30159 Hannover, Germany.
Cancers (Basel). 2020 Mar 30;12(4):833. doi: 10.3390/cancers12040833.
An easy-to-use survival score was developed specifically for older patients with cerebral metastases from colorectal cancer, and was compared to existing tools regarding the accuracy of identifying patients who die in ≤6 months and those who survive for ≥6 months. The new score was built from 57 patients receiving whole-brain irradiation. It included three groups identified from 6-month survival rates based on two independent predictors (performance status and absence/presence of non-cerebral metastases), with 6-month survival rates of 0% (0 points), 26% (1 point), and 75% (2 points), respectively. This score was compared to diagnosis-specific scores, namely the diagnosis-specific graded prognostic assessment (DS-GPA), the Dziggel-Score and the WBRT-30-CRC (whole-brain radiotherapy with 30 Gy in 10 fractions for cerebral metastases from colorectal cancer) score and to a non-diagnosis-specific score for older persons (Evers-Score). Positive predictive values were 100% (new score), 87% (DS-GPA), 86% (Dziggel-Score), 91% (WBRT-30-CRC), and 100% (Evers-Score), respectively, for patients dying ≤6 months, and 75%, 33%, 75%, 60%, and 45%, respectively, for survivors ≥6 months. Of the five tools, the new score and the Evers-Score were most precise in identifying patients dying ≤6 months. The new score and the Dziggel-Scores were best at identifying patients surviving ≥6 months. When combining the results, the new score appeared preferable to the existing tools. The score appears not necessary for patients with additional liver metastases, since their 6-month survival rate was 0%.
专门为患有结直肠癌脑转移的老年患者开发了一种易于使用的生存评分,并将其与现有工具在识别6个月内死亡患者和存活6个月及以上患者的准确性方面进行了比较。新评分基于57例接受全脑照射的患者构建。它包括根据两个独立预测因素(体能状态和有无非脑转移)从6个月生存率确定的三组,6个月生存率分别为0%(0分)、26%(1分)和75%(2分)。将该评分与特定诊断评分,即特定诊断分级预后评估(DS-GPA)、齐格评分和WBRT-30-CRC(针对结直肠癌脑转移采用10次分割给予30 Gy全脑放疗)评分,以及针对老年人的非特定诊断评分(埃弗斯评分)进行比较。对于6个月内死亡的患者,阳性预测值分别为100%(新评分)、87%(DS-GPA)、86%(齐格评分)、91%(WBRT-30-CRC)和100%(埃弗斯评分),对于存活6个月及以上的患者,阳性预测值分别为75%、33%、75%、60%和45%。在这五种工具中,新评分和埃弗斯评分在识别6个月内死亡患者方面最为精确。新评分和齐格评分在识别存活6个月及以上患者方面表现最佳。综合结果来看,新评分似乎比现有工具更具优势。对于有额外肝转移的患者,该评分似乎没有必要,因为他们的6个月生存率为0%。